What Vertex Pharmaceuticals actually looks for
Vertex Pharmaceuticals, headquartered in Boston, Massachusetts, transformed cystic fibrosis treatment with a series of drugs culminating in Trikafta (marketed as Kaftrio in some markets), which addresses the underlying genetic cause of the disease for the majority of patients rather than just managing symptoms, and this focus on disease-modifying rather than purely symptomatic treatment defines Vertex's scientific identity. More recently, Vertex has diversified beyond cystic fibrosis with Casgevy, a CRISPR-based gene-editing therapy developed with CRISPR Therapeutics for sickle cell disease, one of the first approved CRISPR therapies, and Journavx, a non-opioid pain medication approved in 2025 that targets a real, long-standing need for effective pain treatment without opioid risk. Interviewers, especially in R&D roles, expect deep familiarity with the specific science behind these therapies, since Vertex prides itself on tackling diseases at the genetic or mechanistic root rather than pursuing incremental improvements to existing treatment classes. The company's near-total dominance in cystic fibrosis treatment also means candidates should understand the commercial concentration risk that comes with owning most of a therapeutic category.
Common questions and how to answer them
How does Vertex's approach to cystic fibrosis differ from earlier symptomatic treatments? Explain that Trikafta and related drugs target the underlying protein defect (CFTR) rather than just managing symptoms like mucus buildup, a genuinely disease-modifying approach. What does the Casgevy approval mean for Vertex's future pipeline strategy? Show you understand this as a real diversification move into gene editing and hematology, beyond the company's traditional cystic fibrosis focus, developed jointly with CRISPR Therapeutics. How would you think about launching Journavx, a non-opioid pain drug, into a market shaped by the opioid crisis? Discuss the genuine clinical and public health opportunity a non-addictive option represents, balanced against the commercial challenge of changing prescriber habits. For each question, connect your answer to Vertex's stated identity of targeting disease at the root cause, since this is the thread that ties Trikafta, Casgevy, and Journavx together.
How to prepare
Understand the CFTR modulator mechanism behind Trikafta well enough to explain simply why it represented a genuine breakthrough in cystic fibrosis care rather than an incremental improvement. Read about Casgevy's approval and its significance as one of the first real-world CRISPR gene-editing therapies, since it signals Vertex's expansion beyond a single disease area. Follow news on Journavx's launch and market reception, since non-opioid pain treatment is a genuinely novel commercial category with real interviewer interest in how it's going. Expect R&D interviews to probe your understanding of disease mechanism at a fairly deep level, since Vertex hires scientists who can reason from root cause rather than symptom management.